Posts

BJP Bengal gains may boost reforms push

New Delhi: The BJP's latest electoral surge, especially in West Bengal, could spur greater Centre-state policy alignment and aid the Union government's reforms push as the economy grapples with the fallout of the West Asia war and a below-normal monsoon forecast, economists said on Monday.The dominant National Democratic Alliance constituent at the Centre has registered its maiden victory in West Bengal, retained Assam and Puducherry (with alliance partners) and won a record three seats in Kerala. It won only one seat in Tamil Nadu, against four in 2021.Also Read: How BJP's well-oiled vote machine breached Mamata's Bengal fortressBut its win in West Bengal-which has been hit by deindustrialisation and frequent Centre-state rows-remains the most consequential for India's growth prospects, if the winds of political change lead to a raft of economic reforms, the economists said.130810506Centre-state ties switching to cordiality from confrontation could bolster the impl...

TVK surge may trigger shake-up in DMK, AIADMK

from Economic Times https://ift.tt/piPG3Y0

Doda bans protests after Mehraj Malik rally

from Economic Times https://ift.tt/ITzqfLS

How long before Iran breaks under US pressure?

from Economic Times https://ift.tt/7r8XoKm

TN poll results: Vijay emerges as the ultimate X-factor

from Economic Times https://ift.tt/Dptoi2n

Tata dethroned! India’s auto game has a new king

from Economic Times https://ift.tt/rdGhHsX

Hindustan Labs, RK Steel get Sebi nod to launch IPOs

Indian pharmaceutical firm Hindustan Laboratories has received observations from capital markets regulator Sebi, clearing a key step toward its proposed initial public offering (IPO). The IPO comprises a total issue size of up to 14.1 million equity shares with a face value of Rs 10 each. This includes a fresh issue of up to 5 million shares and an offer for sale (OFS) of up to 9.1 million shares by existing shareholders.According to the filing, the company intends to use the net proceeds from the fresh issue primarily to fund its working capital requirements and for general corporate purposes.Hindustan Laboratories operates in the generic pharmaceuticals segment, focusing on the large-scale manufacturing and supply of affordable medicines. Its portfolio mainly consists of generic formulations, drugs whose patents have expired and are typically priced lower than branded alternatives, making them widely accessible.The company’s business model is largely business-to-government (B2G), wit...